newsfilter
← Latest News
PR Newswire·

Shanghai Precision Diagnostics and Fudan University Shanghai Cancer Center Launch Breast Cancer Biomarker Study Using 10x Genomics' Xenium Platform

  • 10x Genomics will deploy its Xenium platform for a 24-month study conducted by Fudan University Shanghai Cancer Center (FUSCC) and Shanghai Precision Diagnostics Co. Ltd (SPDx).
  • The study aims to identify biomarkers that predict how breast cancer patients respond to neoadjuvant therapy, which is treatment administered before surgery to shrink tumors.
  • Researchers plan to analyze pretreatment tumor biopsy samples from 500 patients to profile tumor gene expression & compare findings with treatment outcomes.
  • The Xenium platform will be used to identify cellular features & pathways associated with treatment response or resistance, with potential future expansion to the Atera platform.
  • FUSCC & SPDx intend to use the study findings to inform the development of future diagnostic approaches for personalized treatment decisions.
  • This project exemplifies 10x Genomics' customer-driven strategy path, which enables customers to use its technologies in translational research to develop their own diagnostics.
  • 10x Genomics products are currently for research use only (RUO) & are not authorized for use in diagnostic procedures.
Company
10x Genomics, Inc.
Keywords
10x Genomics, Inc.